谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

197TiP First-in-human (FIH) phase I/II study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC)

K.N. Moore,S. Bouberhan,E. Hamilton,J. Liu,R.E. O'Cearbhaill,D. O'Malley, K. Papadimitriou, D. Schröder,E. Van Nieuwenhuysen,S-Y. Yoo,M. Peterman,P. Goncalves, T. Schmidt, M. Zhu,I. Lowy,T. Uldrick,E.A. Miller

Immuno-Oncology and Technology（2022）

引用 0|浏览5
暂无评分
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要